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Immunogenicity and Reactogenicity of DTPa-IPV/Hib
Vaccine Co-administered With Hepatitis B Vaccine for
Primary and Booster Vaccination of Taiwanese Infants
Pei-Lan Shao,1 Chun-Yi Lu,1 Yu-Chia Hsieh,2 Taiwan Infanrix-069 Study Group,3
Hans L Bock,4 Li-Min Huang1*
Immunogenicity and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated
poliovirus-Haemophilus influenzae type b (Hib) conjugate vaccine (DTPa-IPV/Hib, Infanrix™-IPV + Hib) was
assessed when co-administered with hepatitis B (HBV) vaccine. Seventy healthy infants received DTPa-
IPV/Hib at 1.5, 3.5, 6 and 15–18 months, and HBV at birth, 1.5, 6 and 15–18 months of age. Serological
responses were assessed. Diphtheria, tetanus, Hib and pertussis seroprotection/seropositivity rates were
100% after primary vaccination. Post-primary immune responses to poliovirus could not be evaluated for
technical reasons. However, after the booster dose, seroprotection/seropositivity rates, including po-
liovirus, were 100%. Over 95% were seroprotected against HBV. Post-booster geometric mean antibody
concentrations/titers (GMC/GMTs) rose from 14-fold to 45-fold, indicating effective priming against all
antigens, including polioviruses. DTPa-IPV/Hib was well tolerated alone or co-administered with HBV. No
serious adverse events were considered related to vaccination. Primary and booster vaccination with com-
bined DTPa-IPV/Hib and HBV was immunogenic and well tolerated. Combination vaccines enable vac-
cine providers to conveniently provide routine pediatric immunizations, with minimal discomfort.
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The complex logistics related to the administration
of different multi-dose vaccines has been a signif-
icant barrier to the successful implementation 
of universal immunization programs. Combined
vaccines allow administration of antigens against
multiple diseases in a single injection, and offer
the advantages of convenience, cost-effectiveness
and improved compliance. Combined vaccines
contribute to improved timeliness of vaccination
and improved coverage.1,2
The combined diphtheria-tetanus-acellular
pertussis vaccine [DTPa, Infanrix GlaxoSmithKline
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(GSK) Biologicals] containing three pertussis anti-
gens [pertussis toxin (PT), filamentous haemag-
glutinin (FHA) and pertactin (PRN)] is effective
in preventing pertussis disease,3 and is the basis for
combination vaccines such as combined DTPa-
inactivated poliovirus vaccine (IPV)-Haemophilus
influenzae type b (Hib) conjugate vaccine (DTPa-
IPV/Hib, Infanrix™ IPV + Hib). DTPa-IPV/Hib was
first licensed for use in 1998 and is currently li-
censed in more than 68 countries.
Co-administration of DTPa-IPV-Hib with hep-
atitis B vaccine (HBV) commonly administered
during infancy in many countries, would con-
tribute to improved compliance and vaccine cov-
erage. This study assessed the immunogenicity and
reactogenicity of the DTPa-IPV/Hib vaccine co-
administered with HBV vaccine, when used for pri-
mary and booster vaccination of Taiwanese infants.
Materials and Methods
This open, randomized study was conducted at
the Department of Pediatrics, National Taiwan
University Hospital, Taipei, Taiwan between 02-
02-2001 and 14-11-2002 (Study ID: 217744/069;
ClinicalTrials.gov NCT00880477). Healthy infants
born to mothers seronegative for hepatitis B surface
antigen, were randomized to receive primary vac-
cination with either DTPa-IPV/Hib vaccine or GSK
Biologicals’ experimental DTPa-HBV-IPV/Hib vac-
cine at 1.5, 3.5, 6 and 15–18 months of age. All
subjects received HBV vaccine (Engerix B, GSK
Biologicals, Rixensart, Belgium) at birth. DTPa-IPV/
Hib recipients also received HBV vaccine at 1.5, 6
and 15–18 months of age. This report pertains to
the DTPa-IPV/Hib study group only.
The study was conducted in accordance with
Good Clinical Practice, local regulatory require-
ments and the Declaration of Helsinki. The study
protocol, and related documents were reviewed
and approved by the Ethics Committee of National
Taiwan University Hospital. Written informed con-
sent was provided by the child’s parent/guardian,
prior to enrollment. The composition of the study
vaccines has been previously described.4
Five blood samples were drawn from each sub-
ject: at Month 1.5 and Month 3.5 (prior to and 
2 months after the first DTPa-IPV/Hib dose),
Month 7 (1 month after the third DTPa-IPV/Hib
dose), and prior to and 1 month after the booster
dose. Antibodies against vaccine antigens were
measured using standard methods.5
Specific local and general symptoms were so-
licited for 4 days after each dose using diary cards.
Other unsolicited symptoms were reported for
31 days (days 0–30) after each dose. Serious ad-
verse events (SAEs) were reported from adminis-
tration of the HBV birth dose until 30 days after
the last primary vaccination dose and for 30 days
following administration of the booster dose.
Seropositivity/seroprotection rates and
Geometric Mean antibody Concentrations/Titers
(GMC/ GMTs) with 95% confidence intervals
(CIs) were calculated for antibodies against each
vaccine antigen at each blood sampling time
point. The vaccine/booster response for each
pertussis antigen was calculated 1 month after
the last vaccine dose. A vaccine response (VR)
after primary vaccination was defined as the ap-
pearance of antibodies (concentration ≥ cut-off) in
initially seronegative subjects, or post-vaccination
≥ pre-vaccination antibody concentration in ini-
tially seropositive subjects. A booster response
(BR) after the booster dose was defined as the
appearance of antibodies in subjects seronegative
at the pre-booster time point, or post-booster anti-
body concentrations ≥2-fold pre-booster concen-
trations in subjects seropositive at the pre-booster
time point.
The percentage of doses followed by local and
general solicited symptoms within each 4-day
follow-up period was calculated with exact 95% CIs.
Results
Immunogenicity
Seventy subjects were enrolled and randomized
to receive primary vaccination with DTPa-IPV/Hib.
Of these, seven subjects withdrew consent and two
subjects did not participate in the booster phase
Vaccination with DTPa-IPV/Hib and HBV
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(migrated from the area or refused to participate).
Thus, 62 subjects participated in the booster phase.
The ATP (According to protocol) primary im-
munogenicity analysis comprised 62 subjects (7
subjects were eliminated due to non-compliance
with the vaccination schedule, and 1 subject was
eliminated for protocol violation, having a history
of neonatal seizures prior to enrollment). No
subjects were eliminated from the ATP booster
immunogenicity cohort.
The mean age of infants in the total vacci-
nated cohort at the time of the first DTPa-IPV/
Hib vaccine dose was 6.3 weeks [standard devia-
tion (SD) ± 0.47 weeks]. Thirty-nine (56%) in-
fants were female and all were of Asian origin. The
mean age of subjects at the time of the booster
dose was 16.9 months (SD ± 0.41 weeks).
Table 1 shows the antibody response after
vaccination 1 month after completing 3-dose
primary vaccination with DTPa-IPV/Hib and HBV
vaccines, 95.1% infants had seroprotective levels of
anti-HBs antibodies, 100% had seroprotective an-
tibodies or were seropositive for antibodies against
diphtheria, tetanus, Hib and pertussis, and 87.1%
of subjects reached the 1.0μg/mL cut-off for PRP
(polyribosylribitol phosphate). A VR against PT,
FHA and PRN was observed in all subjects.
The immune response to poliovirus antigens
could not be evaluated after primary vaccination.
Laboratory explorations confirmed a chemical
interference from the sera samples in the po-
liovirus micro-neutralization assay due to the
material and method used for the collection of
blood samples and preparation of sera aliquots.
Poliovirus responses after booster vaccination
are provided below.
With the exception of PT, against which 53.2%
of the subjects remained seropositive, the majority
of subjects had persisting antibodies against vacci-
nation antigens prior to booster dose at 15–18
months of age, including 96.4% of subjects
against poliovirus type 1 and 100% of subjects
against poliovirus types 2 and 3.
One month after the booster dose, 98.4% of
subjects had seroprotective antibody levels against
HBV, 100% had seroprotective antibodies/were
seropositive for the remaining vaccine antigens,
including poliovirus types 1, 2 and 3, and 100%
reached the 1.0 μg/mL anti-PRP antibody cut off.
A BR was observed in 100% of subjects against
PT, 95.2% against FHA and 98.3% against PRN.
One month after the booster dose, increases in
post-booster antibody GMC/GMT of between
14-fold and 46-fold were observed for all vaccine
antigens. For all three polioviruses, the fold in-
crease in antibody GMT after the booster dose
ranged between 14-fold and 21-fold.
Reactogenicity and safety
Local and general symptoms tended to be re-
ported most frequently after the first DTPa-
IPV/Hib vaccine dose, reducing in frequency
after subsequent primary doses (Table 2). Grade
3 local and general symptoms were uncom-
monly reported. Grade 3 fever (> 39.0°C) was re-
ported after no more than 1.6% of primary
doses. Considering all primary vaccination doses
(n = 189) the most frequently reported local and
general grade 3 symptoms were redness > 20 mm
(3.2% of doses overall) and irritability (2.1% of
all doses). The reactogenicity of DTPa-IPV/Hib
administered alone at Dose 2 did not differ sub-
stantially from Dose 1 and Dose 3 when DTPa-
IPV/Hib was co-administered with HBV.
Unsolicited symptoms considered by the in-
vestigator to be related to DTPa-IPV/Hib vaccina-
tion were reported by 7.1% of subjects over the
primary vaccination course. Seven SAEs were re-
ported during the primary phase. None were
considered to be related to vaccination.
At 15–18 months of age, the booster DTP-
IPV/Hib vaccine co-administered with HBV vac-
cine was well tolerated. Grade 3 local symptoms
tended to be reported more frequently after the
booster dose than after primary vaccination doses.
With the exception of fever, the incidence of so-
licited general symptoms after the booster dose
tended to be reduced compared with primary
vaccination doses. Fever after the booster dose
was reported by 30.6% of subjects. However, no
cases of grade 3 fever (> 39.0°C) were reported
after the booster dose.
P.L. Shao, et al
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No subject had an unsolicited event consid-
ered by the investigator to be causally related to
the booster vaccination. No SAEs were reported
between the primary and booster phases, but one
subject reported a SAE after the booster dose. This
event was not considered to be related to vaccina-
tion by the investigator. No deaths occurred dur-
ing the primary or booster phases of the study.
Discussion
Primary and booster vaccination of Taiwanese
infants with the combined DTPa-IPV/Hib vac-
cine co-administered with HBV vaccine was im-
munogenic and well tolerated, with the majority
of infants achieving seroprotective antibody con-
centrations against vaccine antigens. Substantial
increases in antibody GMC/GMT of ≥ 14-fold
observed after the booster dose indicate effective
priming.
Although antibodies against poliovirus types
1, 2 and 3 could not be satisfactorily examined
in the primary vaccination, we observed seropro-
tection rates of 100% against each poliovirus
type after the booster dose, as well as a 14 to 21-
fold increase in antibody GMTs, suggesting prim-
ing had occurred. Furthermore, previous studies
of the IPV component of the DTPa-IPV/Hib vac-
cine have shown seroprotection rates against
each poliovirus type exceeding 98%.5,6,7
The reactogenicity profile of the DTPa-IPV/Hib
vaccine was satisfactory. Grade 3 symptoms were
uncommonly reported. Notably, grade 3 fever
(> 39.0°C) was reported after no more than 1.6%
of primary doses and was not reported at all after
the booster dose. Somewhat higher reactogenicity
observed after the booster dose is in line with the
known characteristics of DTPa-based booster vac-
cines.8,9 No SAEs that occurred during the study
were considered to be related to the study vaccines.
The DTPa-IPV/Hib vaccine has been licensed
for use for over 10 years and extensive clinical expe-
rience documented in countries in Europe and Asia
attest to the acceptability of the vaccine in terms
of its immunogenicity and safety profile.4,10−18
P.L. Shao, et al
420 J Formos Med Assoc | 2011 • Vol 110 • No 6
Ta
b
le
 2
.
In
ci
de
nc
e 
of
 lo
ca
l a
nd
 g
en
er
al
 s
ol
ic
ite
d 
sy
m
pt
om
s 
af
te
r p
rim
ar
y 
an
d 
bo
os
te
r v
ac
ci
na
tio
n 
w
ith
 D
TP
a-
IP
V/
H
ib
 a
t 1
.5
, 3
.5
, 6
 a
nd
 1
5–
18
 m
on
th
s 
an
d 
H
BV
 v
ac
ci
ne
at
 0
, 1
.5
, 6
 a
nd
 1
5–
18
 m
on
th
s 
of
 a
ge
 (T
ot
al
 V
ac
ci
na
te
d 
Co
ho
rt
)
Va
cc
in
e
D
os
e 
1 
(n
=
63
)
D
os
e 
2 
(n
=
63
)
D
os
e 
3 
(n
=
63
)
Bo
os
te
r d
os
e 
(n
=
62
)
Sy
m
pt
om
D
TP
a-
IP
V/
H
ib
+
H
BV
D
TP
a-
IP
V/
H
ib
D
TP
a-
IP
V/
H
ib
+
H
BV
D
TP
a-
IP
V/
H
ib
+
H
BV
In
te
ns
ity
%
95
%
 C
I
%
95
%
 C
I
%
95
%
 C
I
%
95
%
 C
I
Pa
in
A
ny
49
.2
36
.4
–6
2.
1
28
.6
17
.9
–4
1.
3
31
.7
20
.6
–4
4.
7
53
.2
40
.1
–6
6.
0
G
ra
de
 3
0.
0
0.
0–
5.
7
1.
6
0.
0–
8.
5
0.
0
0.
0–
5.
7
8.
1
2.
7–
17
.8
Re
dn
es
s
A
ny
 
33
.3
22
.0
–4
6.
3
31
.7
20
.6
–4
4.
7
38
.1
26
.1
–5
1.
2
48
.4
35
.5
–6
1.
4
>
20
m
m
6.
3
1.
8–
15
.5
3.
2
0.
4–
11
.0
0.
0
0.
0–
5.
7
8.
1
2.
7–
17
.8
Sw
el
lin
g
A
ny
33
.3
22
.0
–4
6.
3
27
.0
16
.6
–3
9.
7
27
.0
16
.6
–3
9.
7
53
.2
40
.1
–6
6.
0
>
20
m
m
4.
8
1.
0–
13
.3
1.
6
0.
0–
8.
5
0.
0
0.
0–
5.
7
11
.3
4.
7–
21
.9
D
ro
w
si
ne
ss
A
ny
71
.4
58
.7
–8
2.
1
38
.1
26
.1
–5
1.
2
31
.7
20
.6
–4
4.
7
33
.9
22
.3
–4
7.
0
G
ra
de
 3
3.
2
0.
4–
11
.0
0.
0
0.
0–
5.
7
0.
0
0.
0–
5.
7
0.
0
0.
0–
5.
8
Irr
ita
bi
lit
y
A
ny
57
.1
44
.0
–6
9.
5
52
.4
39
.4
–6
5.
1
52
.4
39
.4
–6
5.
1
48
.4
35
.5
–6
1.
4
G
ra
de
 3
0.
0
0.
0–
5.
7
4.
8
1.
0–
13
.3
1.
6
0.
0–
8.
5
3.
2
0.
4–
11
.2
Lo
ss
 o
f a
pp
et
ite
A
ny
54
.0
40
.9
–6
6.
6
42
.9
30
.5
–5
6.
0
39
.7
27
.6
–5
2.
8
43
.5
31
.0
–5
6.
7
G
ra
de
 3
0.
0
0.
0–
5.
7
3.
2
0.
4–
11
.0
0.
0
0.
0–
5.
7
3.
2
0.
4–
11
.2
Fe
ve
r (
ax
ill
ar
y)
 
≥
37
.5
°C
 
31
.7
20
.6
–4
4.
7
34
.9
23
.3
–4
8.
0
25
.4
15
.3
–3
7.
9
30
.6
19
.6
–4
3.
7
>
39
.0
°C
0.
0
0.
0–
5.
7
1.
6
0.
0–
8.
5
1.
6
0.
0–
8.
5
0.
0
0.
0–
5.
8
n
=
nu
m
be
r 
of
 s
ub
je
ct
s;
 %
=
pe
rc
en
ta
ge
 o
f s
ub
je
ct
s 
w
ith
 th
e 
sp
ec
ifi
ed
 s
ym
pt
om
; G
ra
de
 3
: p
ai
n 
– 
cr
ie
d 
w
he
n 
th
e 
lim
b 
w
as
 m
ov
ed
/s
po
nt
an
eo
us
ly
 p
ai
nf
ul
, d
ro
w
si
ne
ss
 –
 d
ro
w
si
ne
ss
 th
at
 p
re
ve
nt
ed
 n
or
m
al
 a
ct
iv
ity
,
irr
ita
bi
lit
y 
– 
cr
yi
ng
 th
at
 c
ou
ld
 n
ot
 b
e 
co
m
fo
rt
ed
/p
re
ve
nt
ed
 n
or
m
al
 a
ct
iv
ity
, l
os
s 
of
 a
pp
et
ite
 –
 n
ot
 e
at
in
g 
at
 a
ll;
 9
5%
 C
I=
ex
ac
t 9
5%
 c
on
fid
en
ce
 in
te
rv
al
; D
TP
a-
IP
V/
H
ib
=
co
m
bi
ne
d 
di
ph
th
er
ia
-t
et
an
us
-a
ce
llu
la
r
pe
rt
us
si
s-
in
ac
tiv
at
ed
 p
ol
io
vi
ru
s-
H
ae
m
op
hi
lu
s 
in
flu
en
za
e 
ty
pe
 b
 c
on
ju
ga
te
 v
ac
ci
ne
; H
BV
=
he
pa
tit
is
 B
 v
ac
ci
ne
.
Vaccination with DTPa-IPV/Hib and HBV
J Formos Med Assoc | 2011 • Vol 110 • No 6 421
In the present study we showed that DTPa-IPV/
Hib primary and booster vaccination was immu-
nogenic and well tolerated when co-administered
with HBV vaccine. A range of immunogenic and
well-tolerated combination vaccines, including
DTPa-IPV/Hib and hexavalent DTPa-HBV-IPV/Hib
vaccine,19 are now available. These vaccines en-
able vaccine providers to conveniently provide
routine immunizations to infants and young
children, with a minimum of discomfort. 
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